Rohan Ramakrishna, MD, Chief of Neurosurgery at NewYork-Presbyterian Brooklyn Methodist, has been promoted to Professor of Neurosurgery. Dr. Ramakrishna, who is also Director of the Brain Metastases Program and Co-director of the William Rhodes and Louise Tilzer-Rhodes Center for Glioblastoma at NewYork-Presbyterian, is an award-winning, board-certified neurosurgeon who specializes in the treatment of brain tumors and other central nervous system tumors. He recently co-authored a paper in Nature Medicine with the results of the multi-center CAPTIVE trial (Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects) for recurrent glioblastoma.
“Dr. Ramakrishna joined the faculty in 2014 from MD Anderson Cancer Center,” says Dr. Philip Stieg, Margaret and Robert J. Hariri, MD ’87, PhD ’87 Professor of Neurological Surgery at Weill Cornell Medicine and Chairman and Neurosurgeon-in-Chief of NewYork-Presbyterian/Weill Cornell Medical Center. “For the past nine years he has consistently delivered on his early promise in the field of neuro-oncology. He is an excellent clinician who delivers expert and compassionate care to his patients and also an outstanding academic, with significant research and publications to his credit. I could not be more pleased to welcome him to the rank of full professor.”
Dr. Ramakrishna has a national reputation in the field of neuro-oncology and has published significant research on advances in the field. He is a co-editor of the 2020 textbook Central Nervous System Metastases: Diagnosis and Treatment and has served on the executive committees for AANS/CNS section on Brain Tumors and Society for Neuro-Oncology. He was the Scientific Co-Chair of the International meeting for Brain Metastases Care in 2021 and has been a national thought leader on the management of brain tumor patients in the Covid-19 era. He has also pioneered a new technique for asleep motor mapping of the Rolandic cortex, which has shown to be more reliable than traditional approaches, with reduced risk of seizures.